About: Purification of severe acute respiratory syndrome hyperimmune globulins for intravenous injection from convalescent plasma

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Purification of severe acute respiratory syndrome hyperimmune globulins for intravenous injection from convalescent plasma Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Purification of severe acute respiratory syndrome hyperimmune globulins for intravenous injection from convalescent plasma
Creator	Al, Sars, Article, Purification Globulinszhang,
Source	Medline; PMC
abstract	BACKGROUND: Severe acute respiratory syndrome (SARS) is a new infectious disease caused by the SARS virus. Current first‐line treatments are experimental, and their effectiveness remains open to question. For more effective treatment and prevention of SARS, human SARS hyperimmune globulins for intravenous (IV) injection were purified in this study. STUDY DESIGN AND METHODS: A combination of cold ethanol precipitation and ion‐exchange chromatography was used to process pooled SARS convalescent plasma samples. Virus inactivation and removal approaches were taken to ensure safety. RESULTS: The purified hyperimmune globulins were formulated as a 5 percent solution, with an antibody titer specifically against the SARS virus of 1:83, 1:1600, and 1:200, as determined by enzyme‐linked immunosorbent assay, immunofluorescence assay, and neutralizing antibody test, respectively. The purity of the SARS hyperimmune globulins was 99.0 percent, and the monomer and dimer content was 100 percent. Other variables analyzed met the Chinese Requirements of Biologics for IV immune globulin. The SARS hyperimmune globulins prepared were subsequently approved for clinical evaluation by the Chinese National Institute for the Control of Pharmaceutical & Biological Products. CONCLUSION: IV‐injectable, purified, and concentrated human SARS hyperimmune globulins were prepared from pooled convalescent plasma samples, which are ready to be further evaluated.
has issue date	2005-06-29(xsd:dateTime)
bibo:doi	10.1111/j.1537-2995.2005.00179.x
bibo:pmid	15987362
has license	no-cc
sha1sum (hex)	14171388b33b3d1a296b94fee10c535c54f8c510
schema:url	https://doi.org/10.1111/j.1537-2995.2005.00179.x
resource representing a document's title	Purification of severe acute respiratory syndrome hyperimmune globulins for intravenous injection from convalescent plasma
has PubMed Central identifier	PMC7201861
has PubMed identifier	15987362
schema:publication	Transfusion
resource representing a document's body	covid:14171388b33b3d1a296b94fee10c535c54f8c510#body_text
is schema:about of	named entity 'plasma' named entity 'PKA' named entity 'SEVERE ACUTE RESPIRATORY SYNDROME' named entity 'severe acute respiratory syndrome' named entity 'SARS' named entity 'ethanol precipitation' named entity 'SARS' named entity 'convalescent plasma' named entity 'hepatitis' named entity 'antibody titer' named entity 'globulins' named entity 'convalescent plasma' named entity 'IgG' named entity 'mice' named entity 'globulins' named entity 'plasma' named entity 'ethanol precipitation' named entity '1:2' named entity 'Real-time PCR' named entity 'dimer' named entity 'convalescent plasma' named entity 'antibody titer' named entity 'Triton X-100' named entity 'Biologics' named entity 'antibodies' named entity 'PKA' named entity 'detergent' named entity 'controlled clinical trials' named entity 'individual variation' named entity 'low pH' named entity 'heat stability' named entity 'titer' named entity 'Biologics' named entity 'SARS virus' named entity 'virus' named entity 'IVIG' named entity 'convalescent plasma' named entity 'nucleic acid' named entity 'hepatitis' named entity 'virus' named entity 'hepatitis B antibodies' named entity 'hyperimmune' named entity 'SARS' named entity 'SARS' named entity 'hepatitis' named entity 'guinea pigs' named entity 'SARS' named entity 'antibody' named entity 'Millipore' named entity 'antibody' named entity 'SARS' named entity 'steroid' named entity 'globulins' named entity 'viruses' named entity 'maltose' named entity 'detergent' named entity 'heat stability' named entity 'hyperimmune' named entity 'butyl' named entity 'PKA' named entity 'prekallikrein' named entity 'severe acute respiratory syndrome' named entity 'immunofluorescence assay' named entity 'SARS' named entity 'severe acute respiratory syndrome' named entity 'hepatitis C virus' named entity 'globulins' named entity 'plasma' named entity 'nucleic acid' named entity 'globulins' named entity 'hyperimmune' named entity 'titer' named entity 'SARS' named entity 'peptide cleavage' named entity 'toxicity' named entity 'convalescent plasma' named entity 'antibody' named entity 'chromatography'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software